Author Archive: Tracy Cooley

Tracy Cooley

Tracy serves as the Director of Events Communications and handles all communications for BIO’s events and emerging company policy issues. She loves blogging and podcasting on all things biotech and believes in the great potential of the industry, looking for every opportunity to spread the message far and wide. Nearly everyone in her family is a golfer, and as such, she has what many people have called a “natural” swing. Sometimes she even hits the ball. Tracy just finished her ninth marathon, and has nearly mastered the skill of one-foot-in-front-of-the-other (usually, sometimes the laces get in the way). The joy of her life is her five-year-old daughter Josephine.

Latest Posts

Podcast with Debra Miller, Cure Duchenne

Biotech-Now’s Tracy Krughoff spoke with Cure Duchenne’s President, Debra Miller. Cure Duchenne will be one of the patient advocacy organizations presenting at the Eighth Annual BIO Investor Forum next week. Listen Now!

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Novavax launches study of novel H1N1 vaccine in Mexico

Novavax, Inc. (Nasdaq: NVAX) initiated a two-stage clinical study of its virus-like-particle (VLP) H1N1 influenza vaccine in Mexico in collaboration with Avimex Laboratories (Avimex) and GE Healthcare. Avimex distributes biological and pharmaceutical products for use in Mexico and more than 25 other countries around the world. Avimex is providing financial support for the trial and is expected to distribute the H1N1 VLP vaccine in Mexico in 2010 if it is approved for commercial sale. In Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Clinical trial results for Calistoga Pharmaceuticals’ CAL-101

Calistoga Pharmaceuticals, Inc., announced interim results from the ongoing Phase 1 trial evaluating CAL-101, a PI3K inhibitor, showing promising clinical responses in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). At this interim assessment, 29 percent of CLL patients treated in the cohort expansion dose levels had partial responses observed after 28 days of therapy (1 cycle) and 94 percent have achieved evidence of biologic activity with a greater than 50 percent decrease in Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Endocyte announces close of $26 million equity financing

Endocyte, Inc., completed a $26 million extension of its Series C financing. This round included participation from all existing institutional investors including Sanderling Ventures, Burrill & Company, American Bailey Ventures, Blue Chip Venture Company, and Triathlon Medical Ventures. Clarian Health Ventures also participated as a new investor.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Targacept reports positive Phase 2b trial results for depression treatment

Targacept, Inc. (NASDAQ: TRGT) presented data from its Phase 2b clinical trial of TC-5214 as an augmentation (add-on) treatment in subjects with major depressive disorder who did not respond adequately to first-line treatment with the representative SSRI citalopram hydrobromide.  In the trial, the add-on TC-5214 arm (TC-5214 + citalopram) outperformed the add-on placebo arm (placebo + citalopram) on the primary outcome measure, the Hamilton Rating Scale for Depression-17, or HAM-D, and all of the secondary Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,